You are here : Home / All Sectors / Healthcare / Pharmaceuticals & Drugs / CADILA HEALTHCARE

CADILA HEALTHCARE
Intrinsic Value | Fundamental Analysis

Returns | 1W : 9.6% , 1M : 31.5%,1Y : 67%
BOM : 532321     NSE : CADILAHC    
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive]
Debt : High
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward
Pledged Shares : None or < 25%
Apr 22,2021
Price(EOD): Rs. 552.25
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
MarketCap: Rs. 56,533.83 Cr
Stock Market Investing Simplified- The best Video Course by Smart-Investing.in

Check out Industry Peers

Peers & Returns1W1M1Y
CADILA HEALTHCARE 9.6% 31.5% 67%
SUN PHARMACEUTICAL INDUSTRIES 1.2% 11.4% 36.3%
DR REDDYS LABORATORIES 7.4% 23.5% 34.1%
DIVIS LABORATORIES -0.8% 14.8% 61.7%
CIPLA 3.3% 25.1% 62.3%
BIOCON -1.2% 2.6% 12.1%
AUROBINDO PHARMA 8.6% 23.1% 82.7%
LUPIN 1.1% 6.1% 34.7%
TORRENT PHARMACEUTICALS 0.4% 8.8% 11.6%

FUNDAMENTAL ANALYSIS OF CADILA HEALTHCARE

 
Fundamentals Score
[Last Annual Data : Mar2020 | TTM
Trailing Twelve Months (TTM) is calculated using last 4 quarterly data and is a good substitute to track Annual results.
Learn More
]
Show Me the Stocks with Fundamentals better than CADILA HEALTHCARE Premium


VALUATION OF CADILA HEALTHCARE

 
Valuation Score
RatioValue
P/E
P/B
P/S
48.06
P/E Calculated based on EPS of 11.49
[ Mar2020 - Consolidated Results ]

5.45
P/B Calculated based on Book Value of 101.33
[ Mar2020 - Consolidated Results ]

3.93
P/S Calculated based on Revenues of 14396.7 Cr
[ TTM - Consolidated Results ]

Show Me the Stocks with Valuation better than CADILA HEALTHCARE Premium


FAIR VALUE OF CADILA HEALTHCARE

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
55%
37%
33%

SHARE PRICE MOMENTUM OF CADILA HEALTHCARE

DEBT

Year Debt/Equity ratio
Standalone Consolidated
2020
2019
2018
Avg_3yrs
0.33
0.42
0.37
0.37
0.77
0.76
0.62
0.72
[Last Annual Data : Mar2020]

PLEDGED SHARES

Pledged Shares
0 %
As on : Sep2020

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad

QTRLY RESULTS

Consolidated 1 Qtr Growth 4 Qtr Growth
Revenue
Op Profit
EBIDT
Net Income
-0.64%
-6.34%
17.41%
20.99%
4.33%
16.23%
37.21%
40.64%
QtrlyTrend
4
Latest Qtr: Dec2020

CADILA HEALTHCARE related INDICES

BSE Indices1W1M1Y
S&P BSE HEALTHCARE 3.7% 15.3% 56.9%
S&P BSE MOMENTUM 0.5% 10.6% 36%
S&P BSE ALLCAP -0.8% -0.3% 59.7%
S&P BSE 500 -0.9% -0.4% 58.8%
S&P BSE 250 LARGEMIDCAP -0.9% -0.4% 57.2%
S&P BSE 200 -1% -0.5% 56.9%
S&P BSE LARGE MIDCAP -1% -0.7% 55.6%
S&P BSE DIVIDEND STABILITY -1.1% -0.6% 48.4%
S&P BSE 100 LARGECAP TMC -1.1% -0.7% 53.9%
S&P BSE LARGECAP -1.2% -0.9% 53.7%
NSE Indices1W1M1Y
NIFTY PHARMA 3% 16.2% 46.8%
NIFTY ALPHA LOW-VOLATILTY 30 0.4% 4.3% 39.7%
NIFTY NEXT 50 -0.1% 1.6% 46.2%
NIFTY 100 EQUAL WEIGHT -0.3% 1.2% 60.5%
NIFTY 500 -0.9% -0.4% 58.3%
NIFTY LARGE MIDCAP 250 -0.9% -1.7% 65%
NIFTY 200 -1% -0.4% 55.9%
NIFTY 100 -1.1% -0.7% 53.2%

FAQ [Frequently Asked Questions]


Is CADILAHC good for long term investment?

As on 22-Apr-2021, the Fundamentals of CADILAHC are Strong and hence it's good for long term investment! See Financial Performance of CADILA HEALTHCARE . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is CADILAHC UnderValued or OverValued?

As on 22-Apr-2021, CADILAHC is Over Valued and hence NOT a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of CADILAHC ?

As on 22-Apr-2021, the Intrinsic Value of CADILAHC is Rs. 401.72 determined based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 355.33
Fair Value [Median EV / Sales Model] : Rs. 401.72
Fair Value [Median Price / Sales Model] : Rs. 414.87
Median Fair Value of CADILAHC : Rs. 401.72

Is CADILAHC trading at a Premium or Discount?

As on 22-Apr-2021, CADILAHC is trading at a Premium of 37% based on the Median Intrinsic Value!

Is it right time to buy CADILAHC shares?

As on 22-Apr-2021, CADILAHC is Over Valued and hence NOT a good buying opportunity according to Share Valuation at this time!

What is the Financial Performance of Industry Peers of CADILAHC?

Check out Financials of Industry Peers using below links:
Financials of SUN PHARMACEUTICAL INDUSTRIES LTD
Financials of DR REDDYS LABORATORIES LTD
Financials of DIVIS LABORATORIES LTD
Financials of CIPLA LTD
Financials of BIOCON LTD
Financials of AUROBINDO PHARMA LTD
Financials of LUPIN LTD
Financials of TORRENT PHARMACEUTICALS LTD
Financials of ABBOTT INDIA LTD
Financials of ALKEM LABORATORIES LTD

What are the Frequent Comparisons with CADILAHC?

CADILA HEALTHCARE LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs DR REDDYS LABORATORIES LTD
CADILA HEALTHCARE LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD
CADILA HEALTHCARE LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD
CADILA HEALTHCARE LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs BIOCON LTD
CADILA HEALTHCARE LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs AUROBINDO PHARMA LTD
CADILA HEALTHCARE LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs LUPIN LTD
CADILA HEALTHCARE LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs TORRENT PHARMACEUTICALS LTD
CADILA HEALTHCARE LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs ABBOTT INDIA LTD
CADILA HEALTHCARE LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs ALKEM LABORATORIES LTD

Open Demat Account & Start Investing
    Affiliate Links

Disclosure

SEBI Research Analyst
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].


All Stocks : A - Z

ALL   A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z